Loading search results

Outcome Measures

Primary Outcomes (1)

Protein Synthesis (Murine Cell-Based Experiments, ex-vivo experiments)
Investigators will use human serum obtained from fasted and fed timepoints (-15, 20, 40 and 60 minutes following beverage consumption) to condition cell culture media (20% volume). To determine the effects of using fasted and/or fed 'human-conditioned' culture media on cell protein synthesis, puromycin incorporation (measure of protein synthesis) will be measured via western blot and expressed relative to a no-serum control. A two-way repeated measures ANOVA will be used to analyze outcomes with cycle stage and group (OC vs non-OC) used as factors
60 minutes

Secondary Outcomes (2)

Whole-body protein synthesis
6 hours
Urinary Measures (Muscle Protein Breakdown)
6 hours

Study Arms (4)

Mid-Follicular Phase

EXPERIMENTAL

7-11 days after onset of menses.

Behavioral: Protein tracer drink

Mid-Luteal Phase

EXPERIMENTAL

5-9 days after ovulation (as confirmed with ovulation test kits).

Behavioral: Protein tracer drink

Active pill phase

EXPERIMENTAL

10-20 days after starting new pill cycle.

Behavioral: Protein tracer drink

Interventions

Protein tracer drinkBehavioral

Subjects will be fed a mixed-macronutrient beverage at rest (0.75g/kg lean body mass of carbohydrates; 0.125g/kg lean body mass of protein). Amino acid composition of the protein will be modelled off the composition of egg. Leucine content will be enriched to 5% with \[13 Carbon(13C)\]-leucine.

Active pill phaseMid-Follicular PhaseMid-Luteal PhaseWithdrawal phase

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Study Design

Study Type

interventional

Phase

not applicable

Allocation

RANDOMIZED

Masking

NONE

Purpose

OTHER

Intervention Model

CROSSOVER

Model Details: This study uses a 4-way counterbalanced crossover design. A total 10 young women (Ages: 18-35 years old; 5 per OC and non-OC group) will be recruited and randomized to begin in either the mid-follicular (7-11 days after the onset of menses) or mid-luteal phase (5-9 days after ovulation) if part of non-OC group; and active pill (10-20 days within starting their new pill cycle) or withdrawal phase (at least 48hrs after their last pill) if part of the OC group. Participants of each group will take part in two metabolic trials, one in each phase of their menstrual cycle or pill cycle.

Sponsor Type

OTHER

Responsible Party

PRINCIPAL INVESTIGATOR

PI Title

Associate Professor

Oral Contraceptive vs Menstrual Cycle Ex Vivo Model

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (4)

Mid-Follicular Phase

Mid-Luteal Phase

Active pill phase

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

Withdrawal phase

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (4)

Mid-Follicular Phase

Mid-Luteal Phase

Active pill phase

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

Withdrawal phase

You may not qualify if:

Data Sharing

Source record

Locations